Spotlight on Eptifibatide in Patients with Acute Coronary Syndromes and/or Undergoing Percutaneous Coronary Intervention

被引：0
|
作者：
Monique P. Curran
Gillian M. Keating
机构：
[1] Adis International Limited,
来源：
BioDrugs | 2006年 / 20卷
关键词：
Percutaneous Coronary Intervention; Acute Coronary Syndrome; Abciximab; Unfractionated Heparin; Primary Percutaneous Coronary Intervention;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Eptifibatide (Integrilin®) is a highly specific, reversible, intravenously administered glycoprotein IIb/IIIa receptor antagonist that acts at the final common step of the platelet aggregation pathway.
引用
收藏
页码：63 / 65
页数：2
相关论文
共 50 条
  • [1] Spotlight on eptifibatide in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention
    Curran, MP
    Keating, GM
    [J]. BIODRUGS, 2006, 20 (01) : 63 - 65
  • [2] Spotlight on eptifibatide in percutaneous coronary intervention and acute coronary syndromes
    Plosker, GL
    Ibbotson, T
    [J]. DISEASE MANAGEMENT & HEALTH OUTCOMES, 2004, 12 (03) : 207 - 210
  • [3] Eptifibatide - A review of its use in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention
    Goa, KL
    Noble, S
    [J]. DRUGS, 1999, 57 (03) : 439 - 462
  • [4] Eptifibatide: A review of its use in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention
    Curran, MP
    Keating, GM
    [J]. DRUGS, 2005, 65 (14) : 2009 - 2035
  • [5] Therapeutic use of intravenous eptifibatide in patients undergoing percutaneous coronary intervention: Acute coronary syndromes and elective stenting
    Granada J.F.
    Kleiman N.S.
    [J]. American Journal of Cardiovascular Drugs, 2004, 4 (1) : 31 - 41
  • [6] The role of eptifibatide in patients undergoing percutaneous coronary intervention
    Zeymer, Uwe
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2007, 8 (08) : 1147 - 1154
  • [7] Recurrence rates of acute coronary syndromes in patients undergoing percutaneous coronary intervention
    Hansen, HH
    Aaroe, J
    Hjortshoej, S
    Ravkilde, J
    Rasmussen, K
    [J]. EUROPEAN HEART JOURNAL, 2003, 24 : 75 - 75
  • [8] Early percutaneous coronary intervention, platelet inhibition with eptifibatide, and clinical outcomes in patients with acute coronary syndromes
    Kleiman, NS
    Lincoff, AM
    Flaker, GC
    Pieper, KS
    Wilcox, RG
    Berdan, LG
    Lorenz, TJ
    Cokkinos, DV
    Simoons, ML
    Boersma, E
    Topol, EJ
    Califf, RM
    Harrington, RA
    [J]. CIRCULATION, 2000, 101 (07) : 751 - 757
  • [9] Eptifibatide - A pharmacoeconomic review of its use in percutaneous coronary intervention and acute coronary syndromes
    Plosker, GL
    Ibbotson, T
    [J]. PHARMACOECONOMICS, 2003, 21 (12) : 885 - 912
  • [10] Clopidogrel, prasugrel or ticagrelor in patients with acute coronary syndromes undergoing percutaneous coronary intervention
    Yudi, M. B.
    Clark, D. J.
    Farouque, O.
    Eccleston, D.
    Andrianopoulos, N.
    Duffy, S. J.
    Brennan, A.
    Lefkovits, J.
    Ramchand, J.
    Yip, T.
    Oqueli, E.
    Reid, C. M.
    Ajani, A. E.
    [J]. INTERNAL MEDICINE JOURNAL, 2016, 46 (05) : 559 - 565
12345